{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:49:31Z","timestamp":1758440971479,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.mayocp.2020.05.003","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T09:24:54Z","timestamp":1590053094000},"page":"1553-1556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["In reply\u2014Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0424-4208","authenticated-orcid":false,"given":"Fabian","family":"Sanchis-Gomar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carme","family":"Perez-Quilis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocp.2020.05.003_bib1","doi-asserted-by":"crossref","first-page":"taaa041","DOI":"10.1093\/jtm\/taaa041","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","volume":"27","author":"Diaz","year":"2020","journal-title":"J\u00a0Travel Med"},{"issue":"4","key":"10.1016\/j.mayocp.2020.05.003_bib2","first-page":"369","article-title":"Myocardial infarction increases ACE2 expression in rat and humans","volume":"26","author":"Burrell","year":"2005","journal-title":"Eur\u00a0Heart J"},{"issue":"8","key":"10.1016\/j.mayocp.2020.05.003_bib3","first-page":"1280","article-title":"Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling","volume":"19","author":"Walters","year":"2017","journal-title":"Europace"},{"issue":"6","key":"10.1016\/j.mayocp.2020.05.003_bib4","doi-asserted-by":"crossref","first-page":"e0198144","DOI":"10.1371\/journal.pone.0198144","article-title":"Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease","volume":"13","author":"Ramchand","year":"2018","journal-title":"PLoS One"},{"author":"Lippi","key":"10.1016\/j.mayocp.2020.05.003_bib5"},{"issue":"2","key":"10.1016\/j.mayocp.2020.05.003_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.5582\/ddt.2020.01017","article-title":"Facts and reflections on COVID-19 and anti-hypertensives drugs","volume":"14","author":"Marin","year":"2020","journal-title":"Drug Discov Ther"},{"issue":"8","key":"10.1016\/j.mayocp.2020.05.003_bib7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/2047487320918102","article-title":"2019 CORONAVIRUS: What are the implications for cardiology?","volume":"27","author":"Ferrari","year":"2020","journal-title":"Eur J Prev Cardiol"},{"author":"Mancia","key":"10.1016\/j.mayocp.2020.05.003_bib8"},{"author":"Reynolds","key":"10.1016\/j.mayocp.2020.05.003_bib9"},{"author":"Li","key":"10.1016\/j.mayocp.2020.05.003_bib10"},{"author":"Zhang","key":"10.1016\/j.mayocp.2020.05.003_bib11"},{"issue":"1","key":"10.1016\/j.mayocp.2020.05.003_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng","year":"2020","journal-title":"Emerg Microbes Infect"},{"author":"Yang","key":"10.1016\/j.mayocp.2020.05.003_bib13"},{"issue":"21","key":"10.1016\/j.mayocp.2020.05.003_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.21037\/atm.2016.11.03","article-title":"Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola","volume":"4","author":"Fedson","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.mayocp.2020.05.003_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2020.03.026","article-title":"Angiotensin-converting enzyme 2 and anti-hypertensives (angiotensin receptor blockers and angiotensin converting enzyme inhibitors) in coronavirus disease 2019 (COVID-19) [published online ahead of print April 4, 2020]","author":"Sanchis-Gomar","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.mayocp.2020.05.003_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cca.2020.04.027","article-title":"Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis","volume":"507","author":"Michael Henry","year":"2020","journal-title":"Clin Chim Acta"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619620304730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619620304730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:33:53Z","timestamp":1758418433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619620304730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0025619620304730"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2020.05.003","relation":{},"ISSN":["0025-6196"],"issn-type":[{"type":"print","value":"0025-6196"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In reply\u2014Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2020.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}